Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Scynexis Inc
135ACurrent price
1.19 EUR
-0.012 EUR (-1.00%)
Last closed
1.34 USD
Company
www.scynexis.com
ISIN
US8112922005
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Exchange
Frankfurt Exchange
Capitalization
49 705 588 USD
Yield for 12 month
-24.56 %
1Y
3Y
5Y
10Y
15Y
135A
SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey. Address: 1 Evertrust Plaza, Jersey City, NJ, United States, 07302-6548
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
6.88 USDP/E ratio
–Dividend Yield
–Current Year
+140 141 000 USD
Last Year
+5 091 000 USD
Current Quarter
+660 000 USD
Last Quarter
+736 000 USD
Current Year
+123 707 000 USD
Last Year
+4 463 000 USD
Current Quarter
+660 000 USD
Last Quarter
+736 000 USD
Key Figures 135A
1 year
3 years
5 years
10 years
EBITDA
-51 565 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-26.32 %
PEG Ratio
–
Return On Equity TTM
-48.42 %
Wall Street Target Price
6.88 USD
Revenue TTM
8 566 000 USD
Book Value
1.54 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-62.5 %
Dividend Yield
–
Gross Profit TTM
12 851 000 USD
Earnings per share
-0.76 USD
Diluted Eps TTM
-0.76 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics 135A
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 135A
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:10
Payout Ratio
–
Last Split Date
17.07.2020
Dividend Date
17.07.2020
Stock Valuation 135A
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
1.6795
Enterprise Value Revenue
0.4358
Price Sales TTM
5.8027
Enterprise Value EBITDA
0.0548
Price Book MRQ
0.8492
Financials 135A
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators 135A
For 52 weeks
1.25 USD
3.07 USD
50 Day MA
1.45 USD
Shares Short Prior Month
1 005 552
200 Day MA
1.76 USD
Short Ratio
8.65
Shares Short
965 236
Short Percent
3.37 %
BeatStart